MSCL (Satellos Bioscience Inc.) arrives at its May 20 earnings event carrying one of the more unusual lending-market signatures in recent weeks — and a sharp insider buying pattern that predates the current run.
The borrow story is the sharpest angle right now. Availability collapsed to effectively zero on May 15, with only 0.13% of lending capacity still in use — meaning the pool is almost completely vacant of short supply. That is a dramatic reversal from the prior week, when availability ran at roughly 1,300–1,600% of short interest, signalling ample room to short. The speed of the flip is striking. Shares available to borrow jumped from a tight range to the practical ceiling in a single session, suggesting a large block of previously lent stock was returned all at once rather than a steady trend. Cost to borrow, meanwhile, has eased materially — running near 6% now versus peaks above 10% in mid-April — reinforcing that demand for new short exposure is genuinely light.
Short interest itself is minimal and declining, making it a secondary character in this story. Short interest amounts to roughly 0.015% of the free float, and fell another 0.4% on May 15. That is too small a position to drive any meaningful squeeze dynamic. The ORTEX short score dropped to 26.8 on May 15 — sharply lower than the 37 range it held through the preceding week — consistent with the broader easing of short pressure. Bears have not built a position here.
The more interesting signal heading into the print is the insider buying cluster from earlier in the year. Director Mark Nawacki bought shares on three separate occasions between early March and early April, spending roughly CAD $185,000 in the open market across those transactions. Director Franklin Berger added 24,750 shares in February at CAD $10.10 — close to where the stock trades today at $9.95. Combined, insiders accumulated approximately 49,750 net shares over the past 90 days, worth around $434,000 USD. These are modest absolute sums for a company with an enterprise value near $100M, but the clustering of open-market buys near current prices suggests those closest to the business saw value at these levels.
The one analyst consensus on record pegged a mean price target of CAD $13.50 — implying roughly 35% upside from current levels — but that data is approximately 50 days old and carries no recent analyst changes, so it should be treated as background colour rather than a live call. The stock is down 3% on the week and essentially flat over the past month, recovering from a sharper slide in late March when the prior earnings event triggered a 12.5% single-day drop and a nearly 17% five-day decline. The November 2025 print produced a similar pattern — a 6.8% drop on day one and 5.4% over the week. That consistent post-earnings softness is the context against which tomorrow's print will be measured.
The earnings release will therefore test whether Satellos' clinical narrative has evolved enough to interrupt a pattern of post-results selling — and whether the institutional cohort that built fresh positions in Q1 sees vindication or another setback.
See the live data behind this article on ORTEX.
Open MSCL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
